^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis

Published date:
11/23/2020
Excerpt:
PCYC-1121 (#NCT01980628) was a phase 2, multi-center, open-label, non-randomized trial designed to assess the efficacy and safety of single-agent ibrutinib in patients with relapsed/refractory MZL….We found significantly worse DOR in patients with extranodal MZL with variants in KMT2D (n = 8 in 15 patients with DOR data), with a median DOR of 9.7 months vs not reached in wild type (HR: 7.75) (P = .0260; Figure 5C), and significantly worse PFS in patients with extranodal MZL with variants in CARD11 (n = 5 in 25 patients with PFS data), with a median PFS of 12.1 months vs 28.0 months in wild type (HR: 3.81) (P = .0352; Figure 5D).
DOI:
10.1182/bloodadvances.2020003121
Trial ID: